Diabetes drug may calm inflamed arteries in heart patients
NCT ID NCT05427084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether canagliflozin, a diabetes medication, can reduce inflammation in the arteries of people with type 2 diabetes and stable coronary artery disease. Researchers will compare the drug to a placebo over 6 months in 16 participants. The main goal is to measure changes in artery inflammation using a special imaging scan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
RECRUITINGOttawa, Ontario, K1Y 4W7, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••